Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer

Journal of Clinical Oncology

Volumn 18, Issue 23, 2000, Pages 3986-3992

  Boige, Valérie ^a   Raymond, Eric ^a   Faivre, Sandrine ^a   Gatineau, Michel ^a   Meely, Kathleen ^a   Mekhaldi, S ^a   Pautier, Patricia ^a   Ducreux, Michel ^a   Rixe, Olivier ^a   Armand, Jean Pierre ^a  

^a Daiichi Pharmaceuticals UK Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CAMPTOTHECIN; CAMPTOTHECIN DERIVATIVE; EXATECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; FEVER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

EID: 0034548798     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.23.3986     Document Type: Article

References (23)

1. Plant antitumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata
2. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
3. Action of camptothecin on mammalian cells in cultures
4. Lethal activity of camptothecin sodium on human lymphoma cells
5. Studies on the antitumor activity, mechanism of action, and cell cycle effects of camptothecin
6. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer
7. Treatment of malignant melanoma with camptothecin (NSC-100880)
8. A phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients
9. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
10. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
11. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo
12. Inhibitory activity of camptothecin derivatives against acetylcholinesterase in dogs and their binding activity to acetylcholine receptors in rats
13. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variant cultured in vitro and xenografted into nude mice
14. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant
15. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice
16. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria
17. Simultaneous determination of camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography application to plasma pharmacokinetic studies in cancer patients
18. Phase I and pharmacokinetic (PK) study of DX-8951f, a novel hexacyclic camptothecin (CPT) analog, on a 30 minute infusion daily for 5 day every 3 week schedule
19. Phase I and pharmacokinetic study of DX-8951f, a novel topoisomerase inhibitor
20. Phase I trial of DX-8951f, a novel camptothecin analogue, administered by a 24-hour continuous infusion
21. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer
22. Phase I and pharmacokinetic trial of weekly CPT-11